Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 1/20 | 0.53 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.51 |
| ▸ | OXER1 | Q8TDS5 | 3/20 | 0.50 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 4/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.40 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24235134 | 0.91 | FPR2 (0.56) | FPR2LTB4RALDH1A1LTB4R2OXER1 | |
| SCHEMBL16677932 | 0.89 | FPR2 (0.62) | FPR2LTB4RALDH1A1LTB4R2OXER1 | |
| SCHEMBL26404492 | 0.89 | FPR2 (0.57) | FPR2LTB4RALDH1A1LTB4R2OXER1 | |
| SCHEMBL16677125 | 0.87 | OXER1 (0.53) | FPR2LTB4RALDH1A1LTB4R2OXER1 | |
| SCHEMBL17875058 | 0.87 | OXER1 (0.53) | FPR2LTB4RALDH1A1LTB4R2OXER1 | |
| SCHEMBL12151577 | 0.84 | OXER1 (0.54) | FPR2LTB4RALDH1A1LTB4R2OXER1 | |
| SCHEMBL16675135 | 0.84 | OXER1 (0.54) | FPR2LTB4RALDH1A1LTB4R2OXER1 | |
| SCHEMBL13468198 | 0.84 | OXER1 (0.57) | FPR2LTB4RALDH1A1LTB4R2OXER1 | |
| SCHEMBL20085622 | 0.84 | OXER1 (0.54) | FPR2LTB4RALDH1A1LTB4R2OXER1 | |
| SCHEMBL3404679 | 0.84 | OXER1 (0.54) | FPR2LTB4RALDH1A1LTB4R2OXER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170283388-A1 | 14-HYDROXY-DOCOSAHEXAENOIC ACID COMPOUNDS | THE BRIGHAM & WOMEN'S HOSPITAL INC., | 2017-10-05 | — | — | US | disclosed |
| US-9611239-B2 | 14-hydroxy-docosahexaenoic acid compounds | THE BRIGHAM & WOMEN'S HOSPITAL INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-20150119462-A1 | 14-HYDROXY-DOCOSAHEXAENOIC ACID COMPOUNDS | THE BRIGHAM & WOMEN'S HOSPITAL INC. | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119462-A1 | 14-HYDROXY-DOCOSAHEXAENOIC ACID COMPOUNDS | FASN, FADS2, ALOX15 | FPR2 331/4885LTB4R 115/4885ALDH1A1 546/4885 |
| US-20170283388-A1 | 14-HYDROXY-DOCOSAHEXAENOIC ACID COMPOUNDS | FASN, FADS2, ALOX15 | FPR2 331/4885LTB4R 115/4885ALDH1A1 546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.